

Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030

<https://marketpublishers.com/r/VC73463A74C0EN.html>

Date: September 2025

Pages: 254

Price: US\$ 4,950.00 (Single User License)

ID: VC73463A74C0EN

Abstracts

The global veterinary monoclonal antibodies market is projected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%. The market is experiencing significant growth, driven by the expanding companion animal population and rising pet ownership. Growing concerns about chronic diseases have further boosted the demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. However, the market faces challenges such as rising pet care costs, which can limit treatment adoption. Furthermore, strict regulatory guidelines and lengthy approval times for drugs further restrain market growth. Despite these hurdles, expanding therapeutic indications beyond dermatology and osteoarthritis continues to create new market opportunities.

“By animal type, the canine segment held the highest share in 2024.”

The canine segment held the largest market share in 2024, driven by rising pet dog ownership and increasing spending on animal healthcare. Dogs are highly prone to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, which require frequent dermatological treatments. The growing trend of pet humanization and the demand for premium veterinary care further support market growth. Additionally, advancements in dermatological treatments, including biologics and targeted monoclonal antibody therapies, improve treatment outcomes for dogs, solidifying the segment's dominance in the market.

“By route of administration, the subcutaneous segment is projected to record the highest CAGR between 2025 and 2030.”

The subcutaneous segment is expected to grow at the fastest rate during the forecast period due to its ease of administration and better pet owner compliance. Rising veterinary recommendations for systemic treatments over topical solutions and the ongoing development of new monoclonal antibodies targeting infectious diseases are increasing demand. Moreover, innovations in monoclonal antibodies targeting infectious diseases further support the segment's growth in the veterinary monoclonal antibodies market.

“By product, cytopoint was the leading segment in 2024.”

The cytopoint segment held the largest market share in 2024, driven by its status as the first and only FDA- and EMA-approved monoclonal antibody therapy for treating canine atopic dermatitis. Additionally, the high prevalence of atopic dermatitis in dogs has increased demand for cytopoint due to its proven efficacy, safety profile, and rising adoption by veterinarians. The growing willingness of pet owners to invest in advanced veterinary treatments has further fueled market growth.

“By therapy type, dermatology surpassed other segments in 2024.”

The dermatology segment held the largest market share in 2024 due to the rising prevalence of chronic diseases such as atopic dermatitis in dogs. Additionally, growing awareness of advanced treatment options like Cytopoint by Zoetis (US) has gained significant traction due to its long-lasting relief and minimal side effects in treating allergic and atopic dermatitis in dogs. The willingness to spend on pet healthcare has further driven this market growth.

“By end user, veterinary hospitals/specialty centers are expected to exhibit the fastest growth during the forecast period.”

Veterinary hospitals/specialty centers are expected to grow at the fastest rate, fueled by the rise in veterinary visits and the availability of specialized pet healthcare services. These facilities offer comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical procedures for various conditions. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, boosting demand in this segment.

“North America accounted for the largest share in 2024.”

North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in R&D for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, also drives market growth. The growing demand for premium pet care products further contributes to North America’s dominance in the global veterinary monoclonal antibodies market.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1 – 75%, Tier 2 – 15%, and Tier 3 – 10%

By Designation: C-level – 30%, D-level – 23%, and Other Designations – 47%

By Region: North America – 35%, Europe – 20%, Asia Pacific – 25%, Latin America – 13%, and Middle East & Africa – 7%

The major players operating in the veterinary monoclonal antibodies market are Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US).

Research Coverage

This report examines the veterinary monoclonal antibodies market based on animal type, product, therapy area, route of administration, end user, and region. It also considers factors such as drivers and restraints that influence market growth. The report highlights opportunities and challenges within the market and offers details about the competitive landscape for market leaders. Additionally, it analyzes micro markets concerning their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.

Reasons to Buy this Report

The report can assist both established firms and new or smaller companies in understanding the market dynamics, which can help them increase their market share. Companies purchasing the report may employ one or a combination of the five

strategies listed below.

This report provides insights into the following points:

Analysis of key drivers (increased prevalence of chronic diseases in animals, innovation in monoclonal antibodies targeting infectious diseases, rise in companion animal population and pet ownership, growth in veterinary healthcare expenditure), restraints (regulatory hurdles and long approval timelines, high cost of development and treatment), opportunities (expanding therapeutic indications beyond dermatology and osteoarthritis, novel administration routes for monoclonal antibodies, rising strategic developments among market players in development of veterinary monoclonal antibodies), and challenges (emerging safety concerns and adverse events reporting, and limited species-specific knowledge) influencing the growth of veterinary monoclonal antibodies market

Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the veterinary monoclonal antibodies market

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of monoclonal antibody treatments across regions.

Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary monoclonal antibodies market

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary monoclonal antibodies market

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
 - 1.3.2 INCLUSIONS AND EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Primary sources
 - 2.1.2.2 Key industry insights
 - 2.1.2.3 Breakdown of primaries
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
 - 2.2.2 EPIDEMIOLOGY-BASED APPROACH
 - 2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
 - 2.2.4 TOP-DOWN APPROACH
 - 2.2.5 BOTTOM-UP APPROACH
 - 2.2.6 PRIMARY INTERVIEWS
- 2.3 GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 VETERINARY MONOCLONAL ANTIBODIES MARKET OVERVIEW
- 4.2 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE AND COUNTRY
- 4.3 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2025 VS. 2030
- 4.4 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
- 4.5 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
- 4.6 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2025 VS. 2030 (USD MILLION)
- 4.7 VETERINARY MONOCLONAL ANTIBODIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

- 5.2.1.1 Increasing prevalence of chronic diseases in animals
- 5.2.1.2 Innovations in monoclonal antibodies targeting infectious diseases
- 5.2.1.3 Rise in companion animal population and pet ownership
- 5.2.1.4 Growth in veterinary healthcare expenditure

5.2.2 RESTRAINTS

- 5.2.2.1 Regulatory hurdles and long approval timelines
- 5.2.2.2 High cost of development and treatment

5.2.3 OPPORTUNITIES

- 5.2.3.1 Expanding therapeutic indications beyond dermatology and osteoarthritis
- 5.2.3.2 Novel administration routes for monoclonal antibodies
- 5.2.3.3 Evolving landscape of strategic collaborations and acquisitions

5.2.4 CHALLENGES

- 5.2.4.1 Emerging safety concerns and adverse event reporting
- 5.2.4.2 Limited species-specific knowledge

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.4 PRICING ANALYSIS

- 5.4.1 INDICATIVE SELLING PRICE, BY KEY PLAYER
- 5.4.2 INDICATIVE SELLING PRICE, BY REGION

5.5 SUPPLY CHAIN ANALYSIS

5.6 ECOSYSTEM ANALYSIS

5.7 INVESTMENT AND FUNDING SCENARIO

5.8 TECHNOLOGY ANALYSIS

5.8.1 KEY TECHNOLOGIES

5.8.1.1 Hybridoma technology

5.8.1.2 Recombinant antibody production

5.8.2 COMPLEMENTARY TECHNOLOGIES

5.8.2.1 Long-acting injectables

5.8.3 ADJACENT TECHNOLOGIES

5.8.3.1 RNA-based therapies

5.9 PATENT ANALYSIS

5.9.1 PATENT PUBLICATION TREND

5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS

5.10 TRADE ANALYSIS

5.10.1 IMPORT DATA

5.10.2 EXPORT DATA

5.11 KEY CONFERENCES AND EVENTS, 2025–2026

5.12 REGULATORY LANDSCAPE

5.12.1 REGULATORY FRAMEWORK

5.12.1.1 North America

5.12.1.2 Europe

5.12.1.3 Asia Pacific

5.12.1.4 Latin America

5.12.1.5 Middle East & Africa

5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.13 PORTER'S FIVE FORCES ANALYSIS

5.13.1 BARGAINING POWER OF SUPPLIERS

5.13.2 BARGAINING POWER OF BUYERS

5.13.3 THREAT OF NEW ENTRANTS

5.13.4 THREAT OF SUBSTITUTES

5.13.5 INTENSITY OF COMPETITIVE RIVALRY

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.14.2 KEY BUYING CRITERIA

5.15 UNMET NEEDS/END-USER EXPECTATIONS

5.16 REIMBURSEMENT ANALYSIS

5.17 PIPELINE ANALYSIS

5.18 IMPACT OF AI/GEN AI IN VETERINARY MONOCLONAL ANTIBODIES MARKET

5.18.1 INTRODUCTION

- 5.18.2 MARKET POTENTIAL OF AI IN VETERINARY MONOCLONAL ANTIBODIES
- 5.18.3 AI USE CASES
- 5.18.4 KEY COMPANIES IMPLEMENTING AI
- 5.19 IMPACT OF 2025 US TARIFF
 - 5.19.1 INTRODUCTION
 - 5.19.2 KEY TARIFF RATES
 - 5.19.3 PRICE IMPACT ANALYSIS
 - 5.19.4 IMPACT ON COUNTRY/REGION
 - 5.19.5 IMPACT ON END-USE INDUSTRIES

6 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE

- 6.1 INTRODUCTION
- 6.2 CANINES
 - 6.2.1 INCREASING PREVALENCE OF OSTEOARTHRITIS AND CANINE ATOPIC DERMATITIS TO BOLSTER GROWTH
- 6.3 FELINES
 - 6.3.1 GROWING RECOGNITION OF OSTEOARTHRITIS IN CATS AND SUCCESSFUL LAUNCH OF SOLENSIA TO FUEL MARKET
- 6.4 OTHER ANIMALS

7 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT

- 7.1 INTRODUCTION
- 7.2 LOKIVETMAB (CYTOPOINT)
 - 7.2.1 INCREASING PREVALENCE OF ATOPIC DERMATITIS IN DOGS TO PROMOTE GROWTH
- 7.3 BEDINVETMAB (LIBRELA)
 - 7.3.1 NEED FOR BETTER PAIN MANAGEMENT SOLUTIONS TO EXPEDITE GROWTH
- 7.4 FRUNEVETMAB (SOLENSIA)
 - 7.4.1 ABILITY TO IMPROVE MOBILITY AND COMFORT IN AGING CATS TO AID GROWTH
- 7.5 CANINE PARVOVIRUS MONOCLONAL ANTIBODY (CPMA)
 - 7.5.1 INCREASING ADOPTION OF CPMA BY VETERINARY CLINICS, SHELTERS, AND PET OWNERS TO SPUR MARKET
- 7.6 GILVETMAB
 - 7.6.1 GROWING TREND TOWARD PERSONALIZED, TARGETED TREATMENTS TO FUEL MARKET

7.7 OTHER PRODUCTS

8 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION

8.1 INTRODUCTION

8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION

8.2.1 EASE OF ADMINISTRATION AND LOWER RISK OF TISSUE DAMAGE TO FACILITATE GROWTH

8.3 INTRAVENOUS ROUTE OF ADMINISTRATION

8.3.1 GROWING USE OF IV IN EMERGENCY CASES AND ONCOLOGY TO BOOST MARKET

8.4 ORAL ROUTE OF ADMINISTRATION

8.4.1 RISING INNOVATIONS IN LIVESTOCK APPLICATIONS TO ENCOURAGE GROWTH

9 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA

9.1 INTRODUCTION

9.2 DERMATOLOGY

9.2.1 FAVORABLE SAFETY PROFILE AND IMPROVED EFFICACY TO FOSTER GROWTH

9.3 PAIN MANAGEMENT

9.3.1 RISING NEED FOR ALTERNATIVE DRUG DELIVERY TO AUGMENT GROWTH

9.4 INFECTIOUS DISEASES

9.4.1 GROWING FOCUS ON REDUCED HOSPITALIZATION TO DRIVE MARKET

9.5 ONCOLOGY

9.5.1 INCREASING ADVANCEMENTS IN MONOCLONAL ANTIBODY THERAPIES TO ACCELERATE GROWTH

9.6 OTHER THERAPY AREAS

10 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER

10.1 INTRODUCTION

10.2 VETERINARY HOSPITALS/SPECIALTY CENTERS

10.2.1 RISE IN NUMBER OF VETERINARY SPECIALISTS TO SPEED UP GROWTH

10.3 VETERINARY CLINICS

10.3.1 GROWING PET OWNERSHIP AND PET CARE SPENDING TO FUEL

MARKET

10.4 VETERINARY RESEARCH & ACADEMIC INSTITUTES

10.4.1 INCREASING COLLABORATIVE RESEARCH EFFORTS TO EXPEDITE GROWTH

10.5 OTHER END USERS

11 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

11.2.2 US

11.2.2.1 Strong R&D and early commercial adoption of monoclonal antibodies to drive market

11.2.3 CANADA

11.2.3.1 Growing pet adoption to drive market

11.3 EUROPE

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

11.3.2 GERMANY

11.3.2.1 Established veterinary infrastructure and high rate of pet ownership to aid growth

11.3.3 FRANCE

11.3.3.1 Growing companion animal population to drive market

11.3.4 UK

11.3.4.1 Increasing pet ownership to drive the market

11.3.5 ITALY

11.3.5.1 Strong demand for advanced therapies for companion animals and livestock to augment growth

11.3.6 SPAIN

11.3.6.1 Ongoing research in veterinary biologics to spur growth

11.3.7 NETHERLANDS

11.3.7.1 Emerging pet care sector to contribute to growth

11.3.8 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

11.4.2 JAPAN

11.4.2.1 Increasing awareness about pet health and well-established pet insurance system to drive market

11.4.3 CHINA

11.4.3.1 Expanding pet market to fuel market

11.4.4 INDIA

11.4.4.1 Growing pet adoption and veterinary shortage to drive market

11.4.5 AUSTRALIA

11.4.5.1 Increased spending on veterinary care to support growth

11.4.6 SOUTH KOREA

11.4.6.1 Increasing awareness and adoption of preventive healthcare measures to drive market

11.4.7 NEW ZEALAND

11.4.7.1 Rising awareness of skin disorders to expedite growth

11.4.8 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

11.5.2 BRAZIL

11.5.2.1 Expanding large-scale livestock operations to boost market

11.5.3 MEXICO

11.5.3.1 Increasing demand for targeted biologics in livestock and pets to drive market

11.5.4 REST OF LATIN AMERICA

11.6 MIDDLE EAST & AFRICA

11.6.1 GROWING NUMBER OF COMPANION AND FOOD-PRODUCING ANIMALS TO PROPEL MARKET

11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET

12.3 REVENUE SHARE ANALYSIS, 2022–2024

12.4 MARKET SHARE ANALYSIS, 2024

12.5 BRAND/PRODUCT COMPARISON

12.6 COMPANY VALUATION AND FINANCIAL METRICS

12.6.1 COMPANY VALUATION

12.6.2 FINANCIAL METRICS

12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

12.7.1 STARS

12.7.2 EMERGING LEADERS

12.7.3 PERVASIVE PLAYERS

12.7.4 PARTICIPANTS

12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

12.7.5.1 Company footprint

12.7.5.2 Region footprint

12.7.5.3 Animal type footprint

12.7.5.4 Route of administration footprint

12.7.5.5 Therapy area footprint

12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

12.8.1 PROGRESSIVE COMPANIES

12.8.2 RESPONSIVE COMPANIES

12.8.3 DYNAMIC COMPANIES

12.8.4 STARTING BLOCKS

12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

12.8.5.1 Detailed list of key startups/SMEs

12.8.5.2 Competitive benchmarking of key startups/SMEs

12.9 COMPETITIVE SCENARIO

12.9.1 PRODUCT LAUNCHES AND APPROVALS

12.9.2 DEALS

12.9.3 EXPANSIONS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 ZOETIS SERVICES LLC

13.1.1.1 Business overview

13.1.1.2 Products offered

13.1.1.3 Recent developments

13.1.1.3.1 Product launches and approvals

13.1.1.3.2 Deals

13.1.1.4 MnM view

13.1.1.4.1 Key strengths

13.1.1.4.2 Strategic choices

13.1.1.4.3 Weaknesses and competitive threats

13.1.2 ELANCO

13.1.2.1 Business overview

13.1.2.2 Products offered

13.1.2.3 Recent developments

13.1.2.3.1 Product launches and approvals

- 13.1.2.3.2 Expansions
- 13.1.2.4 MnM view
 - 13.1.2.4.1 Key strengths
 - 13.1.2.4.2 Strategic choices
 - 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 MERCK & CO., INC.
 - 13.1.3.1 Business overview
 - 13.1.3.2 Products offered
 - 13.1.3.3 Recent developments
 - 13.1.3.3.1 Product launches and approvals
 - 13.1.3.3.2 Expansions
 - 13.1.3.4 MnM view
 - 13.1.3.4.1 Key strengths
 - 13.1.3.4.2 Strategic choices
 - 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 ANIMAB
 - 13.1.4.1 Business overview
 - 13.1.4.2 Products offered
 - 13.1.4.3 Recent developments
 - 13.1.4.3.1 Deals
- 13.2 OTHER PLAYERS
 - 13.2.1 VAXXINOVA INTERNATIONAL B.V.
 - 13.2.2 CEVA LOGISTICS
 - 13.2.3 MABGENESIS INC.
 - 13.2.4 DECHRA
 - 13.2.5 BIOGENESIS BAGO
 - 13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 - 13.2.7 VIRBAC
 - 13.2.8 BIOVETA, A.S.
 - 13.2.9 NIPPON ZENYAKU KOGYO CO., LTD.

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
 - 14.3.1 PRODUCT ANALYSIS
 - 14.3.2 COMPANY INFORMATION
 - 14.3.3 GEOGRAPHIC ANALYSIS

- 14.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
- 14.3.5 COUNTRY-LEVEL VOLUME ANALYSIS
- 14.3.6 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
- 14.3.7 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 VETERINARY MONOCLONAL ANTIBODIES MARKET: INCLUSIONS AND EXCLUSIONS

TABLE 2 VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH ASSUMPTIONS

TABLE 3 VETERINARY MONOCLONAL ANTIBODIES MARKET: RISK ANALYSIS

TABLE 4 PET (DOGS AND CATS) OWNERSHIP IN US, 2024

TABLE 5 INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024 (USD)

TABLE 6 INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022–2024 (USD)

TABLE 7 VETERINARY MONOCLONAL ANTIBODIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM

TABLE 8 VETERINARY MONOCLONAL ANTIBODIES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024

TABLE 9 IMPORT DATA FOR HS CODE 300214, BY COUNTRY, 2021–2024 (USD THOUSAND)

TABLE 10 EXPORT DATA FOR HS CODE 300214, BY COUNTRY, 2021–2024 (USD THOUSAND)

TABLE 11 VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026

TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER

TABLE 17 KEY BUYING CRITERIA, BY END USER

TABLE 18 VETERINARY MONOCLONAL ANTIBODIES MARKET: CURRENT UNMET NEEDS

TABLE 19 VETERINARY MONOCLONAL ANTIBODIES MARKET: PIPELINE ANALYSIS

TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 21 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY

MONOCLONAL ANTIBODIES MARKET**TABLE 22 IMPACT ON COUNTRY/REGION DUE TO US TARIFFS****TABLE 23 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)****TABLE 24 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINES, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 25 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FELINES, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 26 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER ANIMALS, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 27 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)****TABLE 28 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR LOKIVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 29 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR BEDINVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 30 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FRUNEVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 31 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINE PARVOVIRUS MONOCLONAL ANTIBODY, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 32 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR GILVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 33 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 34 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)****TABLE 35 COMMERCIALY AVAILABLE MONOCLONAL ANTIBODIES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION****TABLE 36 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 37 COMMERCIALY AVAILABLE MONOCLONAL ANTIBODIES WITH INTRAVENOUS ROUTE OF ADMINISTRATION****TABLE 38 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)****TABLE 39 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)**

TABLE 40 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 41 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 42 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 45 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 46 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 47 AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US, 2023–2024 (USD)

TABLE 48 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY HOSPITALS/SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 50 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 51 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 52 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 53 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)

TABLE 54 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 56 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 57 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 58 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 59 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,

BY END USER, 2023–2030 (USD MILLION)

TABLE 60 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 61 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 62 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 63 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 64 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 65 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 66 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 67 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 68 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 69 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 70 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)

TABLE 71 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 73 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 74 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 75 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 76 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 77 GERMANY: KEY MACROECONOMIC INDICATORS

TABLE 78 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 79 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY

PRODUCT, 2023–2030 (USD MILLION)

TABLE 80 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 81 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 82 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 83 FRANCE: KEY MACROECONOMIC INDICATORS

TABLE 84 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 85 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 86 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 87 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 88 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 89 UK: KEY MACROECONOMIC INDICATORS

TABLE 90 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 91 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 92 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 93 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 94 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 95 ITALY: KEY MACROECONOMIC INDICATORS

TABLE 96 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE 2023–2030 (USD MILLION)

TABLE 97 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 98 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 99 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 100 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END

USER, 2023–2030 (USD MILLION)

TABLE 101 SPAIN: KEY MACROECONOMIC INDICATORS

TABLE 102 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE 2023–2030 (USD MILLION)

TABLE 103 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 104 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 105 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 106 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 107 NETHERLANDS: KEY MACROECONOMIC INDICATORS

TABLE 108 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 109 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 110 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 111 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 112 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 113 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 114 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 115 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 116 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 117 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 118 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)

TABLE 119 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 120 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 121 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 122 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 123 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 124 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 125 JAPAN: KEY MACROECONOMIC INDICATORS

TABLE 126 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 127 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 128 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 129 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 130 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 131 CHINA: KEY MACROECONOMIC INDICATORS

TABLE 132 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 133 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 134 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 135 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 136 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 137 INDIA: KEY MACROECONOMIC INDICATORS

TABLE 138 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 139 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 140 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 141 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 142 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 143 AUSTRALIA: KEY MACROECONOMIC INDICATORS

TABLE 144 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 145 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 146 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 147 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 148 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 149 SOUTH KOREA: KEY MACROECONOMIC INDICATORS

TABLE 150 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 151 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 152 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 153 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 154 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 155 NEW ZEALAND: KEY MACROECONOMIC INDICATORS

TABLE 156 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 157 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 158 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 159 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 160 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 161 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 162 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 163 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 164 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 165 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 166 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)

TABLE 167 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 168 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 169 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 170 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 171 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 172 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 173 BRAZIL: KEY MACROECONOMIC INDICATORS

TABLE 174 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 175 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 176 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 177 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 178 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 179 MEXICO: KEY MACROECONOMIC INDICATORS

TABLE 180 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 181 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 182 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 183 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY

THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 184 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 185 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 186 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 187 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 188 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 189 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 190 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)

TABLE 191 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)

TABLE 192 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 193 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 194 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)

TABLE 195 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 196 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET

TABLE 197 VETERINARY MONOCLONAL ANTIBODIES MARKET: DEGREE OF COMPETITION, 2024

TABLE 198 VETERINARY MONOCLONAL ANTIBODIES MARKET: REGION FOOTPRINT

TABLE 199 VETERINARY MONOCLONAL ANTIBODIES MARKET: ANIMAL TYPE FOOTPRINT

TABLE 200 VETERINARY MONOCLONAL ANTIBODIES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT

TABLE 201 VETERINARY MONOCLONAL ANTIBODIES MARKET: THERAPY AREA FOOTPRINT

TABLE 202 VETERINARY MONOCLONAL ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 203 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 204 VETERINARY MONOCLONAL ANTIBODIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025

TABLE 205 VETERINARY MONOCLONAL ANTIBODIES MARKET: DEALS, JANUARY 2022–JUNE 2025

TABLE 206 VETERINARY MONOCLONAL ANTIBODIES MARKET: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 207 ZOETIS SERVICES LLC: COMPANY OVERVIEW

TABLE 208 ZOETIS SERVICES LLC: PRODUCTS OFFERED

TABLE 209 ZOETIS SERVICES LLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025

TABLE 210 ZOETIS SERVICES LLC: DEALS, JANUARY 2022–JUNE 2025

TABLE 211 ELANCO: COMPANY OVERVIEW

TABLE 212 ELANCO: PRODUCTS OFFERED

TABLE 213 ELANCO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025

TABLE 214 ELANCO: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 215 MERCK & CO., INC.: COMPANY OVERVIEW

TABLE 216 MERCK & CO., INC.: PRODUCTS OFFERED

TABLE 217 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025

TABLE 218 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 219 ANIMAB: COMPANY OVERVIEW

TABLE 220 ANIMAB: PRODUCTS OFFERED

TABLE 221 ANIMAB: DEALS, JANUARY 2022–JUNE 2025

TABLE 222 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW

TABLE 223 CEVA LOGISTICS: COMPANY OVERVIEW

TABLE 224 MABGENESIS INC.: COMPANY OVERVIEW

TABLE 225 DECHRA: COMPANY OVERVIEW

TABLE 226 BIOGENESIS BAGO: COMPANY OVERVIEW

TABLE 227 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW

TABLE 228 VIRBAC: COMPANY OVERVIEW

TABLE 229 BIOVETA, A.S.: COMPANY OVERVIEW

TABLE 230 NIPPON ZENYAKU KOGYO CO., LTD.: COMPANY OVERVIEW

List Of Figures

LIST OF FIGURES

FIGURE 1 VETERINARY MONOCLONAL ANTIBODIES MARKET SEGMENTATION AND REGIONAL SCOPE

FIGURE 2 VETERINARY MONOCLONAL ANTIBODIES MARKET: YEARS CONSIDERED

FIGURE 3 VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH DESIGN

FIGURE 4 VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY PRIMARY SOURCES

FIGURE 5 VETERINARY MONOCLONAL ANTIBODIES MARKET: INSIGHTS FROM PRIMARIES

FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS

FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION

FIGURE 9 VETERINARY MONOCLONAL ANTIBODIES MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024

FIGURE 10 MONOCLONAL ANTIBODIES IN ANIMAL HEALTH: MARKET SIZE ESTIMATION

FIGURE 11 TOP-DOWN APPROACH

FIGURE 12 BOTTOM-UP APPROACH

FIGURE 13 VETERINARY MONOCLONAL ANTIBODY MARKET: CAGR PROJECTIONS

FIGURE 14 DATA TRIANGULATION METHODOLOGY

FIGURE 15 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 16 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)

FIGURE 17 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)

FIGURE 18 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2025 VS. 2030 (USD MILLION)

FIGURE 19 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 20 GEOGRAPHICAL SNAPSHOT OF VETERINARY MONOCLONAL

ANTIBODIES MARKET

FIGURE 21 INCREASING PREVALENCE OF CHRONIC AND ACUTE DISEASES TO DRIVE MARKET

FIGURE 22 CANINES SEGMENT AND US LED NORTH AMERICA MARKET IN 2024

FIGURE 23 CANINES SEGMENT TO CAPTURE LARGEST MARKET SHARE DURING FORECAST PERIOD

FIGURE 24 LOKIVETMAB (CYTOPOINT) SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD

FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 26 DERMATOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD

FIGURE 27 FRANCE TO REGISTER HIGHEST GROWTH IN VETERINARY MONOCLONAL ANTIBODIES MARKET FROM 2025 TO 2030

FIGURE 28 VETERINARY MONOCLONAL ANTIBODIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 29 NEW REVENUE POCKETS FOR PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET

FIGURE 30 VETERINARY MONOCLONAL ANTIBODIES MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 31 VETERINARY MONOCLONAL ANTIBODIES MARKET: ECOSYSTEM ANALYSIS

FIGURE 32 VETERINARY MONOCLONAL ANTIBODIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024

FIGURE 33 VETERINARY MONOCLONAL ANTIBODIES MARKET: PATENT ANALYSIS, JANUARY 2014–MAY 2025

FIGURE 34 TOP APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES PATENTS, JANUARY 2014–MAY 2025

FIGURE 35 VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER

FIGURE 37 KEY BUYING CRITERIA, BY END USER

FIGURE 38 VETERINARY MONOCLONAL ANTIBODIES MARKET: AI USE CASES

FIGURE 39 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET SNAPSHOT

FIGURE 40 ASIA PACIFIC: DOG POPULATION GROWTH, BY COUNTRY, 2024

FIGURE 41 ASIA PACIFIC: CAT POPULATION GROWTH, BY COUNTRY, 2024

FIGURE 42 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS IN

VETERINARY MONOCLONAL ANTIBODIES MARKET, 2023–2024

FIGURE 43 VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024

FIGURE 44 US: VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024

FIGURE 45 RANKING OF KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET, 2024

FIGURE 46 VETERINARY MONOCLONAL ANTIBODIES MARKET: BRAND/PRODUCT COMPARISON

FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 48 EV/EBITDA OF KEY VENDORS

FIGURE 49 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 50 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY FOOTPRINT

FIGURE 51 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 52 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2024)

FIGURE 53 ELANCO: COMPANY SNAPSHOT (2024)

FIGURE 54 MERCK & CO., INC.: COMPANY SNAPSHOT (2024)

I would like to order

Product name: Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/VC73463A74C0EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VC73463A74C0EN.html>